替吉奥及卡培他滨联合奥沙利铂一线治疗晚期大肠癌的近期疗效比较

目的 比较替吉奥联合奥沙利铂(SOX方案)与卡培他滨联合奥沙利铂(XELOX方案)一线治疗晚期大肠癌的有效性和安全性.方法 53例晚期大肠癌患者按拆信封法分为两组,SOX方案组26例,奥沙利铂130 mg/m2静脉滴注3h,第1天；替吉奥40 mg/ m2分早晚2次餐后口服,第1天至第14天,3周为1个周期.XELOX方案组27例,奥沙利铂130 mg/m2静脉滴注3h,第1天；卡培他滨1000 mg/m2分早晚2次餐后口服,第1天至第14天,3周为1个周期.2个周期评价疗效及毒性.结果 53例均可评价疗效,SOX方案组、XELOX方案组的有效(RR)率分别为46.1％(12/26)和48.1％(13/27),疾病控制率为76.9％(20/26)和74.1％(20/27),两组RR差异均无统计学意义(x2=0.013,P=0.909).两组不良反应主要包括血液学毒性、肝肾功能异常、恶心呕吐、腹泻、末梢神经毒性和手足综合征等,以Ⅰ～Ⅱ级为主,均可耐受,其中SOX方案组的恶心呕吐发生率[61.5％(16/26)]明显高于XELOX方案组[33.3％(9/27)](x2=4.462,P=0.035),但XELOX方案组的腹泻、手足综合征发生率[均44.4％(12/27)]则明显高于SOX方案组[19.2％(5/26)、3.8％(1/26)](x2=4.366、P=0.037,x2=11.699、P=0.001).结论 替吉奥联合奥沙利铂与卡培他滨联合奥沙利铂治疗晚期大肠癌的疗效相当,不良反应均可耐受.

Clinical study of oxaliplatin plus TS-1 or capecitabine in the treatment of advanced colon cancer

Objective To investigate the Clinical efficacy and safety of the two chemotherapy regimen based on Oxaliplatin combined with capecitabine or TS-1 in the treatment of advanced colon cancer. Methods 53 advanced colon cancer patients were involved in this study. 26 patients were given the regimen of SOX： Oxaliplatin（130 mg/m2） was administered intravenously in three hours on day 1, while S-1（40 mg/m2） was administered orally twice daily for 14 consecutive days. 27 patients were given the regimen of XELOX： Oxaliplatin Capecitabine was administered intravenously in three hours on day 1, while Capecitabine（1000mg/m2） was administered orally twice daily for 14 consecutive days.The regimens were repeated every 3 weeks. The efficacy and toxicy were evaluated after 2 cycles. Results All the 53 patients were eligille for enrollment and the patients were appreciable for efficacy and toxicy. The objective response rate（ORR） was 46.7% and 48.2% in the SOX regimen and XELOX regimen respectly. The disease control rate （DCR） was 80.0% and 75.9%. The median time to progression （TTP） was 8.9 months and 9.3 months. There were no significent difference. The objective side effects associated with the regimens were bone marrow suppressive, digestive system reaction （diarrhea or vomiting）, peripheral neuropathy and hand-foot syndrome,and mostly graded 1 or 2. Conclusion There were no significent difference in the efficacy in the two chemotherapy regimens. And the side toxicities were all well tolerable.